Last reviewed · How we verify
anti oxidant omega 3
The antioxidant omega 3, marketed by Woman's Health University Hospital, Egypt, holds a niche position in the healthcare market. The key composition patent is set to expire in 2028, providing a period of exclusivity that could help maintain market share. The primary risk lies in the lack of clear primary indication and revenue data, which may limit the drug's commercial potential and investor interest.
At a glance
| Generic name | anti oxidant omega 3 |
|---|---|
| Also known as | omega 3 plus |
| Sponsor | Woman's Health University Hospital, Egypt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy (NA)
- Effect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adults (NA)
- Comfortage - AD Prevention Strategies (NA)
- PET-MRI in Chronic Traumatic Brain Injury (CTBI) (NA)
- Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery. (NA)
- Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer (NA)
- Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort (PHASE4)
- Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti oxidant omega 3 CI brief — competitive landscape report
- anti oxidant omega 3 updates RSS · CI watch RSS
- Woman's Health University Hospital, Egypt portfolio CI